The PARP Inhibitor Study

The PARP Inhibitor Study investigates a class of medicines called PARP inhibitors, which target cancer cells' ability to repair their DNA. Many cancers, especially those with specific genetic mutations like BRCA, rely heavily on this repair process. By blocking PARP enzymes, these drugs cause cancer cells to accumulate damage and ultimately die, while mostly sparing healthy cells. The study aims to evaluate the effectiveness, safety, and potential benefits of PARP inhibitors for treating certain cancers, offering hope for more targeted and less toxic therapies.